Bruno Montanari


Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries.

Bruno graduated in 1998 with a PharmD. from the Université René Descartes, Paris V and in the same year completed a Master’s degree in Strategic Management at HEC.

Prior to joining the firm in 2017, Bruno was a Partner at Omnes Capital (Paris) in charge of life sciences investments for the venture capital team.  His previous venture capital experience was at Atlas Venture (Paris/London) and CDP Capital (Paris/Montreal).  He started his career in 1999 in London, in the healthcare teams of the investment banking divisions of Deutsche Bank and later Merrill Lynch.  Bruno brings a wealth of experience and network, particularly in continental Europe, where he is based.

Bruno sits on the boards of Coave Therapeutics, STORM Therapeutics and Sibylla Biotech.


Portfolio Companies Managed by Bruno:
  • Portfolio Companies Managed by Bruno:
Sibylla Portfolio Image
Coave Square
Storm Therapeutics

Catello Somma


Catello Somma is a Partner at Seroba. He has a background in venture capital and clinical development, with a focus on the biotechnology and medical device industries.

Catello graduated in 2007 summa cum laude from the University of Naples Federico II and in 2014 completed an MBA at POLIMI Graduate School of Management.

Prior to joining the firm in 2024, Catello was at TVM Capital (Munich), involved across different strategies for both biotech and medtech. Before starting a career in venture capital, Catello co-founded a Boston VC-baked biotech start-up (exited), developing therapeutics for oncology and autoimmune diseases. He started his career in 2009 working for different CROs and biotech companies between Italy and Switzerland. Through his previous roles within clinical and corporate development, he is actively contributing with his expertise to driving and supporting new and existing investments across funds and thesis.

Sorry, we couldn't find any posts. Please try a different search.

Jennifer McMahon


Jennifer McMahon is a Partner at Seroba.  She graduated from UCD with an honours degree in Pharmacology in 2010.  Jennifer then entered a Master’s degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation.

Having placed first in her Master’s degree in 2011, Jennifer then joined Seroba’s Investment Team as an Investment Analyst, progressing to Partner in 2022.

In 2019, Jennifer joined the Advisory Board for the European healthcare Businesswomen’s Association.  She is Chair of Level20 Europe and was a founder member of the Ireland Chapter of Level20.  She guest lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons in Ireland.  She is also in high demand as a speaker at Investor/Entrepreneur life science partnering conferences across Europe.

Jennifer sits on the boards of Endotronix, Palliare and Deciphex, is a Board Observer to Shorla Pharma and was previously on the Board of Biosensia prior to its merger with Kypha Diagnostics.

Portfolio Companies Managed by Jennifer:
  • Portfolio Companies Managed by Jennifer:
Deciphex Square
Palliare Portfolio
Endotronix Portfolio
Biosensia Portfolio

Daniel O’Mahony


Daniel O’Mahony is a Partner at Seroba and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.

Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009.

Daniel graduated with a Ph.D. from the National University of Ireland, Cork in 1986 and holds a business degree in technology management from the Smurfit Business School, University College Dublin (2000). He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA, and the Department of Medicine & Experimental Therapeutics at University College Dublin. He has published in several scientific journals and is co-inventor on numerous patent families.

Dr O’Mahony currently sits on the boards of Perfuze, Quanta Dialysis Technologies and Carballo Group Limited. He previously sat on the boards of Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Atlantic Therapeutics (acquired by Caldera Medical), Medlumics, Novate Medical (acquired by BTG),PQ Bypass (acquired by Endologix) and Stokes Bio (acquired by Life Technologies).


Portfolio Companies Managed by Daniel:
  • Portfolio Companies Managed by Daniel:
Perfuze Square
Atlantic Therapeutics Portfolio
Novate Portfolio
Apica Cardiovascular Portfolio
Pq Bypass Portfolio
Quanta Portfolio
Covagen Portfolio
Medlumics Portfolio

Maud Lazare

Partner, Investor Relations

Maud Lazare is a Partner with Seroba with responsibility for Investor Relations. She has a background in private equity and asset management.

Maud graduated from Université Pierre et Marie Curie, Paris VI, with a Masters in Fundamental Mathematics, as well as from Université Paris Dauphine with a Masters in Modelling, Optimisation, Decision and Organisation.

Prior to joining Seroba in 2023, Maud was a Partner with French life science VC, Truffle Capital, where she was responsible for Investor Relations. Her previous experience was at Massena Partners, a family-office where she also held a role at its Private Markets spin-off, Essling Capital. In addition, Maud has held business development roles in asset management firms such as La Française and Richelieu Finance. She began her career as an equity derivatives trader in BNP, based in both Paris and Tokyo.

Sorry, we couldn't find any posts. Please try a different search.

Alan O’Connell


Alan O’Connell is a Partner at Seroba. He has a background in product and business development in the pharmaceutical and biotechnology industries.

Prior to joining the firm in 2003, Alan worked in a variety of product and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and he also spent time in the Pharmacovigilance section at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation.

Alan graduated with a Ph.D. (neuropharmacology) from the National University of Ireland, Galway in 1994 and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals.

Alan sits on the boards of: Crescent Diagnostics, Shorla Pharma and Artica Therapeutics.

He previously sat on the boards of  Fusion Pharmaceuticals (NASDAQ: FUSN), Prexton Therapeutics (acquired by Lundbeck), Veryan Medical (acquired by Otsuka Medical) and Xention (exited via pharma partnerships).

Portfolio Companies Managed by Alan:
  • Portfolio Companies Managed by Alan:
Artica Therapeutics Large Square Logo
Complement Therapeutics Square
Shorla Oncology Square
Prexton Portfolio
Fusion Portfolio
Veryan Med Portfolio
Ario Pharma Portfolio
Xention Portfolio
Crescent Diagnostics Portfolio

Andrew Duignan

Partner & CFO

Andrew Duignan is a Partner and Chief Financial Officer of Seroba. He graduated from Dublin City University in 2005 with an honours degree in Accounting & Finance and became a qualified chartered accountant in 2010.  Andrew is also a qualified tax consultant.

Prior to joining the Seroba team in 2011, Andrew worked as Financial Controller of Appleyard Motors.  Previously, Andrew was a tax consultant in RSM Farrell Grant Sparks and he has also held positions with AIBBNY and Citco Fund Services.

Vicky La Touche-Price

Marketing & Operations

Vicky La Touche-Price joined the Seroba team in 2010.  A graduate of University College Dublin, she studied for her post-graduate diploma in Marketing in Hemel Hempstead in the UK and she also holds a Digital Marketing diploma from the MII in Dublin.

Previously with McDonnell Douglas Aviation Corporation, Guinness Ireland and DHL Worldwide, Vicky has worked in various international marketing roles in Europe and across a number of Gulf States in the Middle East and in the Near East. Vicky is now based back in Ireland and is responsible for operations and marketing for Seroba Life Sciences.

Anita Dipalo


Anita is an Accountant at Seroba. She is a Member of the Association of Chartered Certified Accountants (ACCA) since 2020 and holds a Bachelor of Science Degree from Rochester Institute of Technology, NY in the United States.

Prior to joining the Seroba team in January 2022, Anita worked as a Management Accountant for CFO Services. Previously, she worked as an Assistant Accountant for Comans Beverages ltd. and has also worked as an Income Auditor for Kempinski Hotels.

Dr Jeanne Bolger

Venture Partner

Jeanne Bolger, MB BCh BAO, is a Venture Partner with Seroba.

Jeanne has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD) and Venture Investments.  She spent 11 years in Licensing and Acquisition (L&A), including Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, and before that as Director in the Business Development group at GlaxoSmithKline.

Jeanne spent nearly 10 years (2012-2022) as Vice President Venture Investment in J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. During that period, she was based in London, leading investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer.  She represented JJDC on the Board of Directors of over a dozen companies, including Aelix Therapeutics, Asceneuron SA, Aviado Bio, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, S-Biomedic, Syndesi, T-Rex.  Dr Bolger also represented JJDC’s LP investments in multiple Venture Capital Funds in UK and Europe as well as representing J&J’s interests in other funding vehicles including incubators and accelerators.

Jeanne received her medical degree from University College Dublin.  She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI).  Dr Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres.  She is a visiting lecturer on the MSc Pharmaceutical Medicine at Trinity College Dublin.  Jeanne sits on the Industry Advisory Board of CURAM, the SFI-funded Centre of Excellence charged with designing the next generation of smart medical devices, and on the Advisory Group of the National Health Innovation Hub which focuses on digital innovation in healthcare. She is on the Advisory Board of the Sir Francis Crick Translational Fund (UK), Chair of Board of Directors at Exevir SA (Private, Belgium) and Non-executive Director at Life Healthcare Group Holdings (JSE:LHC).

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top